Core Viewpoint - Vincerx Pharma, Inc. has announced a 1-for-20 reverse stock split of its common stock, effective January 27, 2025, to reduce the number of issued shares and potentially enhance the stock price [1][2]. Summary by Sections Reverse Stock Split Details - The reverse stock split will convert every 20 issued shares into 1 issued share, reducing the total from approximately 44.8 million shares to about 2.2 million shares [2]. - No fractional shares will be issued; stockholders entitled to a fractional share will receive a cash payment instead [2]. - Adjustments will be made to the number of shares underlying outstanding equity awards, warrants, and other agreements [2]. Implementation and Process - Continental Stock Transfer & Trust Company will act as the exchange agent for the reverse stock split [3]. - Registered stockholders will have their positions automatically adjusted, while those with certificate shares will receive instructions from the exchange agent [3]. Company Overview - Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer [5]. - The company's pipeline includes several products in various stages of development, such as VIP943 in Phase 1 and VIP236, which has completed Phase 1 [5]. - Vincerx is headquartered in San Mateo, California, with a research facility in Monheim, Germany [6].

Merger and Strategic Transaction - Vincerx Pharma has entered into a binding term sheet for a proposed merger with Oqory Inc, a clinical-stage company developing ADCs for oncology [1] - Post-merger, Oqory equity holders are expected to own approximately 95% of the combined entity, while Vincerx equity holders will hold about 5% [10] - The transaction includes a minimum fully diluted equity value of $13.66 million for existing Vincerx stockholders and a concurrent offering of at least $20 million in equity securities [10] - Oqory-designated investors will provide interim financing to Vincerx of $1.5 million in two tranches, with $1 million funded immediately and $500,000 to be funded by January 31, 2025 [10] Leadership and Organizational Changes - Dr Ahmed Hamdy has stepped down as CEO but remains Chairman, while Dr Raquel Izumi has taken over as Acting CEO in a consulting capacity [2] - Alexander Seelenberger has stepped down as CFO, with Kevin Hass assuming the role of Acting CFO [2] - Mr Seelenberger will continue to assist the company in a consulting capacity [2] Pipeline and Clinical Development - Oqory’s pipeline includes multiple ADC programs, with two in clinical development and several next-generation ADCs in preclinical stages [4] - OQY-3258, Oqory’s anti-TROP2 ADC, has shown an 83% overall response rate and 100% disease control rate in first-line triple-negative breast cancer [11] - OQY-3258 has completed Phase 1/2 development in over 150 patients with solid tumors and is being evaluated in two Phase 3 studies for breast cancer [11] - Vincerx’s pipeline includes VIP943, a next-generation ADC in Phase 1, VIP236, a small molecule drug conjugate, and enitociclib, a CDK9 inhibitor [5] Financial and Operational Measures - Vincerx is implementing streamlining and cost-control measures, including a workforce reduction, as part of its due diligence and transaction-related work [2] - The merger is subject to customary closing conditions, including due diligence, regulatory approvals, and stockholder approval from both parties [10]

Core Insights - Vincerx Pharma, Inc. is implementing cost-controls and exploring strategic alternatives to advance the Phase 1 study of VIP943, a novel CD123-targeted antibody-drug conjugate [1][2] - The CEO emphasized the potential of VIP943, citing encouraging results from the Phase 1 dose-escalation study, including complete responses in patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome [2] - The company plans to reduce its workforce by approximately 55% to streamline operations and focus resources on the VIP943 program [2][3] Financial Position - As of October 31, 2024, Vincerx had approximately $8.4 million in cash, cash equivalents, and marketable securities [3] Product and Technology Overview - VIP943 is the first ADC from the VersAptx platform, designed to improve efficacy and reduce toxicities associated with traditional ADCs [4] - The VersAptx platform allows for the development of customized bioconjugates targeting various cancer biologies, enhancing the therapeutic index [5] Strategic Alternatives - Vincerx is considering various strategic alternatives, including out-licensing, mergers and acquisitions, and asset sales, to maximize the value of the VIP943 program and the VersAptx platform [2][3]

Revenue Generation - The company has not recognized any revenue to date and does not expect to generate revenue in the foreseeable future[84]. Expenses - Research and development expenses decreased by approximately $2.2 million and $13.0 million for the three and nine months ended September 30, 2024, compared to the same periods in 2023[93]. - General and administrative expenses increased by approximately $0.3 million for the three months ended September 30, 2024, but decreased by approximately $1.4 million for the nine months ended September 30, 2024, compared to the same periods in 2023[94]. - The total operating expenses for the three months ended September 30, 2024, were $7.8 million, a decrease of $1.8 million compared to $9.6 million for the same period in 2023[92]. - The net loss for the three months ended September 30, 2024, was $7.8 million, a decrease of $1.2 million compared to a net loss of $9.0 million for the same period in 2023[92]. Licensing and Milestone Payments - The company paid Bayer a $5.0 million upfront license fee under the Bayer License Agreement and will be responsible for significant development and commercial milestone payments[82]. - The company paid Bayer an upfront license fee of $5.0 million and may owe future milestone payments ranging from $110.0 million to $318.0 million per licensed product, potentially exceeding $1.0 billion for successful commercialization of at least five products[101]. Cash and Capital Resources - As of September 30, 2024, the company had approximately $10.1 million in cash, cash equivalents, and marketable securities, and raised $16.9 million in April 2024 through stock sales[102]. - Net cash used in operating activities for the nine months ended September 30, 2024, was approximately $19.9 million, with a net loss of approximately $22.1 million during the same period[113]. - Cash flows from investing activities for the nine months ended September 30, 2024, included $11.5 million in purchases of marketable securities, offset by $4.5 million in sales and maturities[114]. - The company entered into an ATM Agreement allowing for the sale of up to $50.0 million in common stock, with approximately $47.5 million remaining available as of September 30, 2024[115]. - On April 30, 2024, the company closed a public offering raising approximately $14.8 million from the sale of 6.0 million shares of common stock and accompanying warrants[116]. - The company expects to need additional capital prior to the one-year anniversary of its unaudited financial statements due to existing cash resources and anticipated operating losses[109]. - The company anticipates that cash used in operating activities may decrease in the near term due to capital constraints, but could increase again if additional funding is obtained[112]. Risk Management - The company has not been exposed to material risks from interest rate changes or foreign currency fluctuations, as operations are primarily in U.S. dollars[122][123]. - The company is unable to estimate exact operating capital requirements due to various uncertainties in research, development, and commercialization processes[104]. Future Expectations - The company expects operating expenses in 2024 to be comparable to 2023, subject to raising additional capital[100]. - The company intends to prioritize resources towards advancing Phase 1 studies of VIP943 while controlling discretionary spending in other areas[100]. - Interest income decreased to $0.2 million for the three months ended September 30, 2024, from $0.3 million for the same period in 2023[97]. - The change in fair value of warrant liabilities for the three months ended September 30, 2024, was primarily due to an increase in the volatility of the company's common stock[96].

Financial Performance - Vincerx Pharma reported a net loss of approximately $7.8 million, or $0.17 per share, for Q3 2024, compared to a net loss of approximately $9.0 million, or $0.42 per share, in Q3 2023[9]. - The company had approximately $10.1 million in cash, cash equivalents, and marketable securities as of September 30, 2024, down from approximately $16.3 million as of June 30, 2024[9]. - Total operating expenses for Q3 2024 were approximately $7.8 million, down from $9.6 million in Q3 2023[15]. Research and Development - Research and development expenses for Q3 2024 were approximately $3.9 million, a decrease from approximately $6.1 million in Q3 2023, primarily due to reduced research services and personnel-related expenses[9]. - VIP943, a CD123-targeted ADC, is in a Phase 1 dose-escalation study, showing promising safety and efficacy with two complete responses reported[4]. - Enitociclib, a CDK9 inhibitor, achieved a 57% overall response rate in a Phase 1 study, with four partial responses in seven patients[6]. - VIP236 completed its Phase 1 dose-escalation study with a 45% disease control rate, demonstrating a favorable safety profile[8]. - The company expects to share additional Phase 1 study data for VIP943 by early 2025[5]. Strategic Initiatives - Vincerx is actively seeking strategic partnerships to advance its ADC technologies and programs[2]. - The company aims to secure funding and explore financing options to support its clinical programs[2].

Core Viewpoint - Vincerx Pharma, Inc. (VINC) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][2]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [3][5]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [3]. Company Performance Indicators - The upgrade reflects an improvement in Vincerx Pharma's underlying business, suggesting that investors may respond positively by driving the stock price higher [4]. - For the fiscal year ending December 2024, Vincerx Pharma is expected to earn -$0.78 per share, representing a 58.7% change from the previous year [7]. - Over the past three months, the Zacks Consensus Estimate for Vincerx Pharma has increased by 38.7%, indicating a positive trend in earnings estimates [7]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks which have averaged a +25% annual return since 1988 [6]. - The upgrade to Zacks Rank 2 places Vincerx Pharma in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [9].

Core Insights - Vincerx Pharma announced promising results from the Phase 1 dose-escalation study of VIP943, showing two complete responses in patients with relapsed/refractory acute myeloid leukemia (AML), higher-risk myelodysplastic syndrome (HR-MDS), and B-cell acute lymphoblastic leukemia (B-ALL) [1][2] - The company is focusing resources on the continued development of VIP943, with an expected cash runway into early 2025 [1][3] VIP943 Data Highlights - The ongoing Phase 1 study has enrolled 22 patients, with 9 patients receiving at least three doses of VIP943 at an efficacious dose of ≥1.0 mg/kg, resulting in a 44% retention rate [2] - Two patients achieved complete remission based on international consensus response criteria, underscoring the significance of these early results [2] - VIP943 demonstrated favorable safety and tolerability, with no dose-limiting toxicities reported and serious adverse events consistent with expectations for this patient population [3] Pharmacodynamics and Pharmacokinetics - Target engagement was confirmed with a maximal receptor occupancy of 84% in the highest dose cohort (1.3 mg/kg), and concurrent decreases in CD123+ peripheral blood blasts were observed [4] - Preliminary pharmacokinetic data shows low release of the payload (≤1% in plasma) and a half-life of less than 96 hours, prompting evaluation of twice weekly dosing [4][5] VIP236 Update - VIP236, a first-in-class small molecule drug conjugate, has enrolled 29 patients in its Phase 1 study, with a disease control rate of 45% among evaluable patients [7] - The drug continues to show a favorable safety profile, with no instances of common dose-limiting side effects associated with camptothecins [7] Enitociclib Update - Enitociclib, a selective CDK9 inhibitor, is being evaluated in a Phase 1 study in combination with venetoclax and prednisone, reporting a 57% overall response rate in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma (PTCL) [10][11] Corporate Webcast - Vincerx will host a corporate webcast to provide updates on its pipeline, including initial clinical data from the Phase 1 study of VIP943, followed by commentary from key opinion leader Dr. M. Yair Levy [12]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to | --- | --- | |-------------------------------------------------------------------------------------------------------------|------------- ...

Vincerx Pharma Reports Second Quarter 2024 Financial Results Exhibit 99.1 Vincerx continues to enroll its Phase 1 studies of antibody-drug conjugate (ADC) VIP943, with data expected by the end of Q4 2024, and small molecule drug-conjugate (SMDC) VIP236, with data expected at the end of Q3 2024 Expected cash runway through 2024 PALO ALTO, Calif., August 8, 2024 – Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradi ...

Vincerx continues to enroll its Phase 1 studies of antibody-drug conjugate (ADC) VIP943, with data expected by the end of Q4 2024, and small molecule drug-conjugate (SMDC) VIP236, with data expected at the end of Q3 2024 Expected cash runway through 2024 PALO ALTO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial result ...